>     News   Solvay Pharmaceuticals Awarded $298 Million, Five-Year Contract by U.S. Department of Health and Human Services for Flu Pandemic Preparedness May 04, 2006   Solvay Pharmaceuticals announced today that it was awarded a $298 million, five-year contract from the United States Department of Health and Human Services (HHS) to develop cell-based influenza vaccines and plan for domestic manufacturing capacity in the U.S.     Solvay Pharmaceuticals, Inc. Submits Drug Master File for Cell-Derived Influenza Vaccine to U.S. Food and Drug Administration June 07, 2005   Solvay Pharmaceuticals, Inc. announced today that it has submitted a drug master file (DMF) to the U.S. Food and Drug Administration (FDA) for its cell-derived influenza vaccine.